Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect test helps you quickly and confidently determine the next steps for treatment.
Confidently guide treatment decisions in mCRPC
Not all mCRPC patients respond to androgen receptor (AR)-targeted therapies, like abiraterone and enzalutamide.1 When AR-targeted therapy fails, acquired resistance could be the cause.1
Image shows a possible mCRPC treatment path
The only predictive and prognostic test for patients with mCRPC, the AR-V7 Nucleus Detect® test:
- Accurately identifies patients who may not benefit from AR-targeted therapies2,3
- Predicts improved overall survival with taxanes versus AR-targeted therapies2,3
- Provides easy-to-interpret results (a positive or negative result)
Why the AR-V7 Nucleus Detect Test for Your mCRPC Patients?
The Oncotype DX AR-V7 Nucleus Detect test is an assay that identifies patients who may not respond to androgen receptor (AR)-targeted therapy and should receive chemotherapy or other therapies instead.1-4
Get fast results from a simple blood draw
The Oncotype DX AR-V7 Nucleus Detect test is a liquid biopsy assay that analyzes circulating tumor cells in a patient's blood. No intrusive or complicated procedures are required. The results are reported to the ordering physician through a secure portal, confirming the patient as either AR-V7-positive (AR-V7+) or AR-V7-negative (AR-V7-).
Is your patient eligible?
The Oncotype DX AR-V7 Nucleus Detect test is for patients who:
- Have confirmed mCRPC
- Have received and failed AR-targeted therapy
- Are considering additional AR-targeted therapies
Coverage and financial assistance
The AR-V7 Nucleus Detect test is widely accessible, with minimal out-of-pocket costs for most patients.*
*The Oncotype DX AR-V7 Nucleus Detect test is reported on claims with the unique Current Procedural Terminology (CPT) code, 81479.
-
References
